Direct and indirect costs among employees with diabetic retinopathy in the United States

Current Medical Research and Opinion

Volumn 24, Issue 5, 2008, Pages 1549-1559

  Lee, Lauren J ^a   Yu, Andrew P ^b   Cahill, Kevin E ^b   Oglesby, Alan K ^c   Tang, Jackson ^b   Qiu, Ying ^b   Birnbaum, Howard G ^b  

^a ELI LILLY AND COMPANY   (United States)

^b ANALYSIS GROUP   (United States)

^c AMGEN INC   (United States)

Author keywords

Diabetic macular edema; Diabetic retinopathy; Health care costs; Photocoagulation; Vitrectomy

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; INSULIN DERIVATIVE; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG COST; EMPLOYEE; FEMALE; HEALTH CARE COST; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; LASER COAGULATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; UNITED STATES; VITRECTOMY;

ADULT; AGE FACTORS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; COST OF ILLNESS; DIABETIC RETINOPATHY; DIRECT SERVICE COSTS; EMPLOYER HEALTH COSTS; EVALUATION STUDIES AS TOPIC; FEMALE; HEALTH BENEFIT PLANS, EMPLOYEE; HUMANS; MALE; MIDDLE AGED; REFERENCE VALUES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SICK LEAVE; STATISTICS, NONPARAMETRIC; UNITED STATES; WORKERS' COMPENSATION;

EID: 44349135017     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079908X297303     Document Type: Article

References (26)

1. Cowie C, Rust K, Byrd-Holt D, et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population. Diabetes Care 2006;29:1263-8
2. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). National diabetes statistics. Available from http://diabetes.niddk.nih.gov [Last accessed 16 Apr 2007]
3. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53
4. Ettaro L, Songer T, Zhang P, Engelgau M. Cost-of-illness studies in diabetes mellitus. Pharmaeconomics 2004;22:149-64
5. Brandle M, Zhou H, Smith B, et al. The direct medical cost of type 2 diabetes. Diabetes Care 2003;26:2300-4
6. Lavigne J, Phelps C, Mushlin A, Lednar W. Reductions in individual work productivity associated with type 2 diabetes mellitus. Pharmaeconomics 2003;21:1123-34
7. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008;31:1-20
8. Ramsey S, Summers K, Leong S, et al. Productivity and medical costs of diabetes in a large employer population. Diabetes Care 2002;25:23-9
9. Fong D, Aiello L, Ferris F, Klein R. Diabetic retinopathy. Diabetes Care 2004;27:2540-53
10. Klein R, Klein B, Moss S, Curickshanks J. The Wisconsin epidemiologic study of diabetic retinopathy: XVII: the 14-year incidence and progression of diabetic retinopathy and associated risk factors in type I diabetes. Ophthalmol 1998;105:1801-15
11. Eye Diseases Prevalence Research Group. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 2004a;122:552-63
12. Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 2004b;122:477-85
13. Ciulla T, Amador A, Zinman B. Diabetic retinopathy and diabetic macular edema. Diabetes Care 2003;26:2653-4
14. Diabetes Control and Complications Trial (DCCT) Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86
15. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
16. Dwyer MS, Melton LJ, Ballard DJ, et al. Incidence of diabetic retinopathy and blindness: a population-based study in Rochester, Minnesota. Diabetes Care 1985;8:316-22
17. Porta M, Bandello F. Diabetic retinopathy: a clinical update. Diabetologia 2002;45:1617-34
18. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985;103:1796-806
19. Javitt JC, Aiello LP. Cost-effectiveness of detecting and treating diabetic retinopathy. Ann Intern Med 1996;124:164-9
20. Klein R. Prevention of visual loss from diabetic retinopathy. Surv Ophthalmol 2002;47(Suppl 2):246-52
21. American Academy of Ophthalmology. Diabetic retinopathy: preferred practice pattern 2003. Available from http://one.aao.org/asset.axd?id=244b5ed4- 38fa-40f6-adf8-55c861836229 [Last accessed March 27, 2008]
22. Rein D, Zhang P, Wirth K, et al. The economic burden of major adult visual disorders in the United States. Arch Ophthalmol 2006;124:1754-60
23. Charlson ME, Pompei P, Ales KL, McKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987;40:373-83
24. Williams R, Van Gaal L, Lucioni C. Assessing the impact of complications on the costs of Type II diabetes. Diabetologia 2002;45:S13-7
25. von Ferber L, Koster I, Hauner H. Medical costs of diabetic complications total costs and excess costs by age and type of treatment results of the Germon CoDiM Study. Exp Clin Endocrinol Diabetes 2007;115:97-104
26. Birnbaum H, Leong S, Oster E, et al. Cost of stress urinary incontinence: a claims data analysis. Pharmacoeconomics 2004;22:95-105